Tuesday, July 31, 2018

LXRX On Watch, NKTR To Face FDA In May, TNDM Boosts Sales Outlook

Today's Daily Dose brings you news about second quarter financial results of GenMark, Illumina and Tandem; anticipated milestones of Lexicon Pharma; Nektar's regulatory catalyst and FDA approval of Progenics' radioactive therapeutic Azedra, among others.

from RTT - Biotech https://ift.tt/2M1aLPo
via IFTTT

No comments:

Post a Comment